Daphni Backs Graph Therapeutics' Human Immune Cell Drug Discovery Platform

• Daphni backed Graph Therapeutics through its Blue fund to develop a drug discovery platform using living human immune cells.
• The operational platform has mapped approximately 1,000 disease-perturbation states across five disease areas.
• Graph aims to identify drug targets and evaluate treatment candidates using patient-derived samples before clinical trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daphni SAS published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.